Domov › Rakovina krvi › Massachusetts › Boston
Klinické štúdie Rakovina krvi v meste Boston, MA
25 štúdií pre Rakovina krvi hľadá účastníkov v zariadeniach v meste Boston a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Prebieha náborObservačná štúdia
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Prebieha náborFáza 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Prebieha nábor
- Massachusetts General Hospital, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Prebieha nábor
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Prebieha náborFáza 2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Prebieha náborFáza 1
- Beth Israel Deaconess Medical Center, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Dana Farber Cancer Institute, Boston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Prebieha náborFáza 2
- Brigham and Women's Hospital, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Prebieha náborVítaní zdravých dobrovoľníkov
- Dana-Farber Cancer Institute, Boston
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Prebieha náborFáza 3
- Tufts Medical Center, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Prebieha náborObservačná štúdia
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
IVIG for Infection Prevention After CAR-T-Cell Therapy
Prebieha náborFáza 2
- Massachusetts General Hospital Cancer Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Prebieha náborObservačná štúdia
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Prebieha náborFáza 1
- Dana Farber Cancer Institute, Boston
Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
Prebieha nábor
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Prebieha nábor
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Prebieha náborFáza 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Prebieha nábor
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Prebieha nábor
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Prebieha náborFáza 1
- Dana-Farber Cancer Institute, Boston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Prebieha náborFáza 1
- Dana-Farber Cancer Institute, Boston
Štúdie Rakovina krvi v iných mestách
- Houston, TX46 štúdií
- New York City, NY26 štúdií
- Washington, DC19 štúdií
- Seattle, WA18 štúdií
- Baltimore, MD18 štúdií
- Los Angeles, CA17 štúdií
- Durham, NC16 štúdií
- Chicago, IL15 štúdií
- Philadelphia, PA14 štúdií
- Columbus, OH13 štúdií
- Edison, NJ13 štúdií
- Nashville, TN13 štúdií
Iné štúdie v Boston
- Rakovina prsníka112 štúdií
- Nemalobunkový karcinóm pľúc90 štúdií
- Rakovina (všetky typy)85 štúdií
- Metastatická rakovina63 štúdií
- Kolorektálny karcinóm63 štúdií
- Rakovina pľúc62 štúdií
- Rakovina vaječníkov61 štúdií
- Rakovina prostaty59 štúdií
- Depresia52 štúdií
- Rakovina endometria50 štúdií
- Srdcové zlyhanie44 štúdií
- Akútna myeloidná leukémia44 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.